Drugs / OR502
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06090266 | Oct 2023 → Aug 2026 overdue | cutaneous melanoma, metastatic malignant neoplasm, non-small cell lung carcinoma | OncoResponse, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OR502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06090266 ↗ |
| Modality | Monoclonal antibody | “IgG1 monoclonal antibody” NCT06090266 ↗ |
| Route | Intravenous | “Escalating repeated doses of OR502 by IV administration” NCT06090266 ↗ |
| Target | LILRB2 | “binds specifically to the LILRB2 protein” NCT06090266 ↗ |